Latest Newsletter, page-11

@applefoot.
Tkx for sharing ! Very well constructed newsletter highlighting the tremendous potential of drugs for anti-inflammation. Before this, I wouldn’t expect the 3 biggest selling drugs are for anti - inflammation. Hope the Mkt will read it favourably.

I particularly like the following extract.
Patience will be warded

...... Current mRNA vaccines use a chemical modification step that reduces TLR7 activation, but that step also reduces the manufacturing yield of the vaccine. The Pharm-RNA technology potentially replaces the current chemical modification step, with the aim of providing greater mRNA vaccine yields and better reduction of inflammatory side-effects. Pharmorage and HIMR believe this will allow the use of higher doses of mRNA as a way of boosting vaccine effectiveness without increasing risk to the individual.Pharmorage plans on putting this opportunity to the test in mRNA vaccines in animal studies using several TLR7-inhibiting oligonucleotides already identified. Armed with that data, Pharmorage then will reach out to all companies involved in mRNA vaccine manufacture.While mRNA vaccine technology is being focused on the pandemic in the short term, it is anticipated that mRNA vaccine technology will become more widely adopted from 2025 onwards.The mRNA vaccine market is forecast to reach up to $30 billion by 2035 with prophylactic vaccines valued at $15B and therapeutic vaccines at $10B .......